Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy
Retina, cilt.30, sa.10, ss.1698-1703, 2010 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 10
- Basım Tarihi: 2010
- Doi Numarası: 10.1097/iae.0b013e3181da4354
- Dergi Adı: Retina
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1698-1703
- Anahtar Kelimeler: central serous chorioretinopathy, photodynamic therapy, verteporfin
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Purpose: The purpose of this study was to evaluate the results of fluorescein angiog-raphy-guided photodynamic therapy with half-dose verteporfin in the treatment of chronic central serous chorioretinopathy with focal leakage areas. Methods: Eight cases with a history of central serous chorioretinopathy of ≥6 months were included. All eyes had one or more focal areas of active retinal pigment epithelial leak. Photodynamic therapy was applied with half-dose verteporfin (3 mg/m), and the spot size was set limited to the area of active leakage shown on fluorescein angiography. Results: The mean duration of the last central serous chorioretinopathy episode was 12.50 months. The mean best-corrected visual acuity improved from 20/122 to 20/60 the first month (P = 0.017) and to 20/55 the first year after treatment (P = 0.018). Seven eyes (87.5%) had improved vision 1 year after treatment, and 1 eye (12.5%) had stable vision with a mean number of 3.61 gained lines. The mean central macular thickness was reduced from 366 ± 95 μm to 217 ± 32 μm the first month (P = 0.006). Conclusion: Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin seems to be a rational and effective alternative to other methods in the treatment of chronic central serous chorioretinopathy with focal leakage on fluorescein angiography. Copyright © 2010 Lippincott Williams & Wilkins. All rights reserved.